Isotretinoin Drugs Market - Forecast till 2027

List of Tables

Market Forecast

The global isotretinoin drugs market is anticipated to register a significant CAGR of 4.68% during the forecast period to surpass a market value of USD 1,652.40 million by the end of 2027.

The global isotretinoin drug market is expected to register a notable market expansion during the review period owing to the growing incidences of acne among people and neuroblastoma. Additionally, the emergence of micronized formation for serious recalcitrant nodular acne cure creates lucrative scope for the global market. Besides, the concerns relating to drug side-effects are anticipated to hamper the global market growth.

The admission of isotretinoin drug presents wellbeing gambles among pregnant ladies. The medication can cause a few birth deformities, for example, the congenital fissure and inherent heart deserts among others. Likewise, unnatural birth cycle and stillbirth are a portion of the significant incidental effects set off by the utilization of the isotretinoin drug. Different confusions impeding the isotretinoin drugs market incorporate dry skin, seriously dried out lips, nosebleeds, dry and disturbed eyes, and dry mouth. The medicine was additionally answered to cause transitory secondary effects like deteriorating of skin inflammation, night visual impairment, diminishing hair, and muscle or joint agony. Also, rashes, stomach issues, and unfortunate cholesterol levels are the interesting conceivable aftereffects that singular encounters during the admission of isotretinoin drugs.

Market Segmentation

The Global Isotretinoin Drugs Market is classified based on Form, indication, distribution channel, and others. By form segment, the global market has been bifurcated into Injection and Capsule.

Based on Indication the market is classified into Severe acne, Squamous cell carcinoma, cutaneous T-cell lymphoma, Neuroblastoma, Harlequin ichthyosis, Xeroderma pigmentosum, and Fibrodysplasia ossificans progressive.

The Distribution Channel divides the market into three main types namely Hospital pharmacies, Retail Pharmacies, and Online pharmacies.

Region-Specific Analysis

North America represented a market size of USD 468.76 million of every 2020 and is relied upon to show a 5.06% CAGR during the review time frame. The isotretinoin drugs market is filling in the area because of created medical care framework, good unofficial laws, the rising pervasiveness of different skin issues, hereditary issues, and malignant growth, as well as expanded R&D venture.

The Asia-Pacific isotretinoin drugs market is relied upon to develop at a CAGR of 6.18% somewhere in the range of 2021 and 2027. The presence of a few market players in the region, for example, Sun Pharma organization (India) and Dr. Reddy's Laboratories Ltd (India), is driving the territorial market development. Moreover, because of the expansion in financing from financial backers, the utilization of isotretinoin is ceaselessly ascending among the clients in more burdened regions, with Asia seeing a relatively higher expansion being used.

Major Players

The key players in the global isotretinoin drugs market are Teva Pharmaceuticals Industries, Akorn (US), Catalent Pharma Solutions (US), Chongqing Huapont (China), Inc. (Israel), Dr. Reddy's Laboratories (India), Douglas Pharmaceuticals Ltd (New Zealand), F. Hoffmann La Roche (Europe)., Mylan (US), Cipher Pharmaceuticals (US), GlaxoSmithKline (UK), and Sun Pharmaceuticals (India).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Product Code: MRFR/HC/2418-CR

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 INCREASING PREVALENCE OF ACNE AMONG TEENS AND YOUNG ADULTS
- 4.2.2 INCREASING INCIDENCE OF NEUROBLASTOMA
4.3 RESTRAINT
- 4.3.1 CONCERNS PERTAINING TO DRUG SIDE EFFECTS
4.4 OPPORTUNITY
- 4.4.1 INTRODUCTION OF NEW MICRONIZED FORMATION FOR SEVERE RECALCITRANT NODULAR ACNE TREATMENT

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION & SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON ISOTRETINOIN DRUGS MARKET
- 5.3.1 IMPACT ON SUPPLY CHAIN
- 5.3.2 IMPACT ON THE ISOTRETINOIN DRUGS MARKET
- 5.3.3 IMPACT ON GDP AND HEALTHCARE EXPENDITURE
5.4 OFF LABEL USAGE OF ISOTRETINOIN CAPSULES
5.5 BY INDICAITION ANALYSIS ON PRESCRIBED PERSONNEL AND DOSAGE

6 GLOBAL ISOTRETINOIN DRUGS MARKET, BY FORM

6.1 OVERVIEW
6.2 CAPSULE
6.3 INJECTION

7 GLOBAL ISOTRETINOIN DRUGS MARKET, BY INDICATION

7.1 OVERVIEW
7.2 SEVERE ACNE
7.3 SQUAMOUS CELL CARCINOMA
7.4 CUTANEOUS T-CELL LYMPHOMA
7.5 NEUROBLASTOMA
7.6 HARLEQUIN ICHTHYOSIS
7.7 XERODERMA PIGMENTOSUM
7.8 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
7.9 OTHERS

8 GLOBAL ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL

8.1 OVERVIEW
8.2 HOSPITAL PHARMACIES
8.3 RETAIL PHARMACIES
8.4 ONLINE PHARMACIES

9 GLOBAL ISOTRETINOIN DRUGS MARKET, BY REGION

9.1 OVERVIEW
9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 FRANCE
- 9.3.3 UK
- 9.3.4 ITALY
- 9.3.5 RUSSIA
- 9.3.6 SPAIN
- 9.3.7 UKRAINE
- 9.3.8 REST OF EUROPE
9.4 ASIA-PACIFIC
- 9.4.1 CHINA
- 9.4.2 INDIA
- 9.4.3 JAPAN
- 9.4.4 SOUTH KOREA
- 9.4.5 AUSTRALIA
- 9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
- 9.5.1 MIDDLE EAST
- 9.5.2 AFRICA
- 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW
10.2 COMPETITIVE BENCHMARKING
10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL ISOTRETINOIN DRUGS MARKET
10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL ISOTRETINOIN DRUGS MARKET
10.5 KEY DEVELOPMENT ANALYSIS
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 PRODUCT LAUNCHES/PRODUCT APPROVALS
- 10.6.2 EXPANSIONS
10.7 FINANCIAL MATRIX
- 10.7.1 SALES (USD MILLION), 2020
- 10.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2020

11 COMPANY PROFILES

11.1 DOUGLAS PHARMACEUTICALS LIMITED
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS/SERVICES OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
11.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS/SERVICES OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 SWOT ANALYSIS
- 11.2.6 KEY STRATEGIES
11.3 AKORN OPERATING COMPANY LLC
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS/SERVICES OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 KEY STRATEGIES
11.4 DR. REDDY'S LABORATORIES LTD
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS/SERVICES OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 SWOT ANALYSIS
- 11.4.6 KEY STRATEGIES
11.5 F. HOFFMAN LA ROCHE LTD
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS/SERVICES OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 SWOT ANALYSIS
- 11.5.6 KEY STRATEGIES
11.6 MYLAN NV
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS/SERVICES OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 KEY STRATEGIES
11.7 SUN PHARMACEUTICALS
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 SWOT ANALYSIS
- 11.7.6 KEY STRATEGIES
11.8 CIPHER PHARMACEUTICALS INC.
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL ANALYSIS
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 KEY STRATEGIES
11.9 GLAXOSMITHKLINE PLC
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL ANALYSIS
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 SWOT ANALYSIS
- 11.9.6 KEY STRATEGIES
11.10 CHONGQING HUAPONT
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL ANALYSIS
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGIES
11.11 CATALENT PHARMA SOLUTIONS
- 11.11.1 COMPANY OVERVIEW
- 11.11.2 FINANCIAL ANALYSIS
- 11.11.3 PRODUCTS OFFERED
- 11.11.4 KEY DEVELOPMENTS
- 11.11.5 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES
12.2 RELATED REPORTS